(Sharecast News) - Eli Lilly and Company posted a surge in fourth-quarter revenues on Thursday, fuelled by strong demand for its blockbuster diabetes and weight-loss drugs.
The US pharmaceutical firm said volume growth from tirzepatide drugs Mounjaro and Zepbound had helped drive revenues up by 45% to $13.5bn.

Obesity drug...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE